Comparative bioavailability studies on some brands of ampicillin capsules

Area of Science:

• Pharmacokinetics and Drug Bioequivalence
• Pharmaceutical Sciences
• Clinical Pharmacology

Background:

• Assessing the bioequivalence of generic drugs is crucial for ensuring therapeutic equivalence to innovator products.
• Ampicillin capsules are widely prescribed antibiotics, necessitating reliable generic alternatives.
• Penbritin (ampicillin) serves as the innovator reference product for comparative studies.

Purpose of the Study:

• To evaluate the bioequivalence of two previously untested generic ampicillin capsule formulations.
• To compare the bioavailability of generic ampicillin products against the innovator brand, Penbritin.
• To determine if generic ampicillin formulations meet regulatory standards for therapeutic equivalence.

Main Methods:

• A bioavailability study was conducted in nine healthy volunteers.
• A randomized, cross-over design was employed, with each participant receiving a 250 mg capsule of ampicillin.
• Statistical analysis using Analysis of Variance (ANOVA) was performed on the collected bioavailability data.

Main Results:

• One generic ampicillin product (ampicillin X) demonstrated a statistically significant difference (p < 0.05) in bioavailability compared to Penbritin.
• The second generic ampicillin product (ampicillin Helm) showed no significant difference in bioavailability relative to Penbritin.
• These findings indicate potential variability in the performance of generic ampicillin formulations.

Conclusions:

• Ampicillin Helm can be considered bioequivalent to Penbritin, suggesting comparable therapeutic efficacy.
• Ampicillin X did not meet the bioequivalence criteria compared to Penbritin, raising concerns about its clinical performance.
• Further investigation may be warranted for ampicillin X to ensure patient safety and treatment effectiveness.